Somewhat Favorable News Coverage Somewhat Unlikely to Affect Laboratory Corp. of America (LH) Share Price
Media stories about Laboratory Corp. of America (NYSE:LH) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Laboratory Corp. of America earned a news impact score of 0.18 on Accern’s scale. Accern also gave news articles about the medical research company an impact score of 47.4243765985162 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Laboratory Corp. of America Holdings (LH) Expected to Announce Quarterly Sales of $2.74 Billion (americanbankingnews.com)
- Report: Triad city sees 41 percent jump in available tech jobs (bizjournals.com)
- LabCorp to Host Investor and Analyst Day on February 27, 2018 (finance.yahoo.com)
- Laboratory Corp. of America Holdings (LH) Expected to Announce Earnings of $2.59 Per Share (americanbankingnews.com)
- Laboratory Corp. of America Holdings (LH) Expected to Earn FY2020 Earnings of $13.01 Per Share (americanbankingnews.com)
Shares of Laboratory Corp. of America (NYSE LH) traded down $0.65 during trading hours on Wednesday, hitting $173.76. 428,959 shares of the company were exchanged, compared to its average volume of 657,210. The firm has a market cap of $18,099.02, a P/E ratio of 14.23, a price-to-earnings-growth ratio of 1.50 and a beta of 0.93. The company has a quick ratio of 1.20, a current ratio of 1.31 and a debt-to-equity ratio of 0.93. Laboratory Corp. of America has a 1-year low of $134.19 and a 1-year high of $181.71.
Several research analysts recently issued reports on LH shares. Robert W. Baird set a $183.00 price target on shares of Laboratory Corp. of America and gave the stock a “hold” rating in a research report on Thursday, February 8th. Zacks Investment Research downgraded shares of Laboratory Corp. of America from a “buy” rating to a “hold” rating in a research report on Friday, October 27th. Barclays restated a “buy” rating and set a $195.00 target price on shares of Laboratory Corp. of America in a research report on Wednesday, December 13th. Craig Hallum restated a “buy” rating and set a $180.00 target price (up from $175.00) on shares of Laboratory Corp. of America in a research report on Thursday, October 26th. Finally, Deutsche Bank upped their target price on shares of Laboratory Corp. of America from $170.00 to $172.00 and gave the company a “buy” rating in a research report on Thursday, October 26th. Six investment analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $180.73.
In related news, CFO Glenn A. Eisenberg sold 8,400 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $167.36, for a total value of $1,405,824.00. Following the sale, the chief financial officer now directly owns 15,931 shares in the company, valued at approximately $2,666,212.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Adam H. Schechter sold 1,263 shares of the stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $169.29, for a total transaction of $213,813.27. Following the completion of the sale, the director now owns 7,297 shares in the company, valued at $1,235,309.13. The disclosure for this sale can be found here. Company insiders own 0.90% of the company’s stock.
Laboratory Corp. of America Company Profile
Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).
Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.